by Chengqun Sun, Christina Gardner, Long Kwan Metthew Lam, Jeneveve Lundy, Katherine O’Malley, Thomas Luke, Kanakatte Raviprakash, Amy L. Hartman, Nicholas A.
Crossland, Hua Wu, Jin-an Jiao, Christoph Bausch, Eddie Sullivan, Douglas S. Reed, William B.
Klimstra Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne RNA virus that causes low mortality but high morbidity in humans. In addition to natural outbreaks, there is potential for exposure to VEEV via aerosolized virus particles.
Currently there are no FDA-licensed vaccines or antiviral therapies for VEEV. We previously demonstrated that high titer anti-VEEV human antibody preparations derived from the plasma of hyperimmunized transchromosomic (Tc) bovines provided significant protection to mice from subcutaneous and aerosol challenge with virulent VEEV (Gardner et al., J.
Virol. , 91:e00226-17, 2017).
In the current studies we utilized the cynomolgus macaque primate model of VEEV infection, challenging some treatment groups with either a IA/B clade virus or a IC clade virus, each derived from a cDNA clone. Animals were treated with liquid or lyophilized transchromosomic bovine polyclonal antibody (TcpAb) preparations via intravenous (IV) or intranasal (IN) routes.
PLOS ONE (Medicine) published a clinical update in Research Highlights on 27 Apr 2026.
The item focuses on A single dose of purified human antibody from transchromosomic bovines mitigates aerosolized Venezuelan equine encephalitis virus disease in cynomolgus macaques.
Review the original article for the full source wording and details.